Raynaud Phenomenon Secondary to Systemic Sclerosis

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Raynaud Phenomenon Secondary to Systemic Sclerosis trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 4

NCT07112183

Open Label Treprostinil Raynaud's Study

Raynaud's phenomenon is a condition where the blood vessels in participants fingers and toes get too narrow when cold or stressed. This makes participants finge…

United States30 participantsStarted 2025-10-15

Treatment: Oral treprostinil (UT-15C) sustained release tablets

All recent trials (22 shown)

CompletedPhase 3

NCT04040322

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of iloprost on the frequency of and relie…

United States198 participantsStarted 2019-10-14

Treatment: Placebo IV infusion, Iloprost Injection, for intravenous use

CompletedPhase 2

NCT03867097

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

This is a Phase 2, multicenter, double-blind, randomized, placebo-controlled study to evaluate the effect of iloprost on the symptomatic relief of Raynaud's Phe…

United States34 participantsStarted 2019-03-07

Treatment: Placebo IV infusion, Iloprost Injection, for intravenous use

Raynaud Phenomenon Secondary to Systemic Sclerosis

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Open Label Treprostinil Raynaud's Study

All recent trials (22 shown)

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Open Label Treprostinil Raynaud's Study

All recent trials (22 shown)

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis

A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Se…

Cold Challenge With C21 in RP

Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis

PF-00489791 For The Treatment Of Raynaud's

Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud

Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to S…

Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon

Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon

Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet

A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon

The Effect of Physical Therapy on Raynaud's Phenomenon Secondary to Systemic Sclerosis

Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction

Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon

Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon

Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon

Lab Study of MQX-503 in Treatment of Raynaud's

Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon